Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.
作者信息
Weyer Karin, Falzon Dennis, Jaramillo Ernesto
机构信息
Global Tuberculosis Programme, World Health Organization, 1211 Geneva 27, Switzerland.
出版信息
Bull World Health Organ. 2018 Oct 1;96(10):667-667A. doi: 10.2471/BLT.18.223230.
Abstract
摘要
相似文献
1
Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.
Bull World Health Organ. 2018 Oct 1;96(10):667-667A. doi: 10.2471/BLT.18.223230.
2
Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis.
Lancet Glob Health. 2019 Jun;7(6):e706. doi: 10.1016/S2214-109X(19)30186-X. Epub 2019 Apr 17.
3
Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
Am J Respir Crit Care Med. 2016 Oct 15;194(8):1028-1029. doi: 10.1164/rccm.201605-1080LE.
4
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031. doi: 10.1164/rccm.201606-1097LE.
5
Efficacy and safety of regimens for drug-resistant tuberculosis.
Lancet Infect Dis. 2016 Nov;16(11):1218-1219. doi: 10.1016/S1473-3099(16)30390-5.
6
WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.
Lancet. 2016 Jun 18;387(10037):2486-7. doi: 10.1016/S0140-6736(16)30729-2.
7
Revolutionary new treatment regimens for multidrug-resistant tuberculosis.
Lancet Infect Dis. 2019 Mar;19(3):233-234. doi: 10.1016/S1473-3099(19)30060-X.
8
The Revised National Tuberculosis Control Programme in India: time for revision of treatment regimens and rapid upscaling of DOTS-plus initiative.
Natl Med J India. 2008 Jul-Aug;21(4):187-91.
9
World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1211-1213. doi: 10.5588/ijtld.17.0199.
10
Multidrug resistant TB: fully oral regimens should help improve compliance, says WHO.
BMJ. 2018 Aug 21;362:k3610. doi: 10.1136/bmj.k3610.
引用本文的文献
1
Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment.
J Family Med Prim Care. 2021 Dec;10(12):4607-4608. doi: 10.4103/jfmpc.jfmpc_2502_20. Epub 2021 Dec 27.
2
Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review.
Pharmacoecon Open. 2020 Jun;4(2):223-233. doi: 10.1007/s41669-019-0162-z.
3
Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach.
Indian J Pediatr. 2019 Aug;86(8):717-724. doi: 10.1007/s12098-018-02846-8. Epub 2019 Jan 17.
本文引用的文献
1
An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.00803-2016. Print 2017 Mar.
Zotero 插件